UCSF home page UCSF home page About UCSF UCSF Medical Center
UCSF navigation bar
photos

The SCOPE Study

The SCOPE study is an ongoing pathogenesis oriented cohort of over 1500 HIV infected and uninfected persons. Our overall goal is to provide a platform for linking the basic laboratory with the clinic. This type of work—which is generally referred to as “translational research”—is often difficult to perform, as basic scientists rarely have the requisite expertise to do clinical research and clinicians often lack the expertise to perform laboratory-based research. The tremendous advances that routinely occur in the laboratory are hence rarely transferred to patient care. To address these concerns, our group has assembled a large cohort of well characterized HIV-infected and uninfected persons of diverse demographic and clinical backgrounds. An extensive biologic specimen repository and clinical data-base have been assembled. These resources are routinely shared with collaboration investigators at UCSF and elsewhere.

In the same spirit of insuring that scientific discoveries lead to therapies for patients, the SCOPE cohort has been constructed to support early clinical testing of novel ideas. We have performed several “first-in-human” studies of such approaches, often working closely with the San Francisco community to make sure the study is both relevant and safe. Along these lines, the SCOPE team is now supporting several studies aimed at reducing HIV-associated inflammation during therapy. We are also supporting small clinical trials aimed at reducing the size of the reservoir. Our long-term aim is to help find a cure for HIV infection.

The field sites for SCOPE are the HIV/AIDS clinic of the San Francisco General Hospital (SFGH) and the San Francisco Veterans Affairs Medical Center (SFVAMC). As a cohort conceived in the contemporary treatment era, SCOPE is designed as a dynamic cohort to allow recruitment based upon the interests of the collaborating scientists. For example, a concerted effort was made by the study directors to respond to the growing interest in those rare individuals who are able to control HIV replication in the absence of any therapy (“elite” controllers). We are also enriching our study for those individuals who fail to exhibit robust CD4+ T cell reconstitution despite otherwise effective therapy. Finally, HIV-uninfected “healthy” subjects have also been enrolled in SCOPE as a valuable comparator to the HIV-infected individuals.

Subjects enrolled in SCOPE are seen every 4 months for a confidential questionnaire regarding medications, symptoms, quality of life, and high risk behaviors. Blood is collected at every visit. SCOPE participants are also asked to participate in additional studies assessing the impact of HIV infection on cardiovascular, kidney, neurologic and gastrointestinal function.

The SCOPE cohort is directed by Drs. Steven Deeks, Jeffrey Martin, Hiroyou Hatano, Peter Hunt, Priscilla Hsue and Harry Lampiris.

For questions or to inquire about enrollment, please call the SCOPE staff at (415) 476-4082 x 140.

Recent Papers
  1. Deeks SG, McCune JM. Can HIV be cured with stem cell therapy? Nat Biotechnol. 2010 Aug; 28(8):807-10.
  2. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010 Jul 3; 376(9734):49-62.
  3. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011 Apr 1; 203(7):960-8.
  4. Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, Hunt P, Deeks SG, Telenti A, Pereyra F, Goldstein D, Wolinsky S, Walker B, Young HA, Carrington M. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature. 2011 Apr 28; 472(7344):495-8.
  5. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011 May 15; 203(10):1474-83.
  6. Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, Ho JE, Selby V, Madden E, Martin JN, Deeks SG, Ganz P, Waters DD. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol. 2012 Mar 1; 109(5):742-7.